HSCS

HeartSciences Inc. (HSCS) - 10-K Filing Summary

Business Context and Reporting Period

Company: HeartSciences Inc.
Filing Type: Form 10-K (Annual Report)
Fiscal Year Ended: April 30, 2025
Business Overview: HeartSciences is a medical technology company developing AI-based electrocardiogram (ECG) algorithms to detect cardiac dysfunction. Its primary products are the MyoVista wav ECG (a 12-lead hardware device) and the MyoVista Insights Cloud Platform (a device-agnostic software platform). Neither product has received FDA clearance for marketing as of the filing date. The company is classified as an "Emerging Growth Company" and a "Smaller Reporting Company."

Key Financial Metrics (Fiscal 2025 vs. Fiscal 2024)

Note: Revenue is minimal and derived primarily from international distributor relationships during the development phase. The company has not generated significant revenue from U.S. sales due to the lack of FDA clearance.

Material Changes and Operational Highlights

• Increased Operating Costs: Research and Development (R&D) expenses increased by 52% to $4.4 million, driven by consulting costs for the Cloud Platform and FDA submission preparation. Selling, General, and Administrative (SG&A) expenses rose 15% to $4.0 million, largely due to professional fees associated with a withdrawn S-1/A registration statement.
• Debt Financing: The company entered into a $2.51 million unsecured note with Streeterville Capital in September 2024. Additionally, the maturity of the FRV Note was extended to September 30, 2025.
• Capital Raising: Subsequent to the fiscal year-end, the company commenced a Series D Preferred Stock offering, raising approximately $3.1 million in gross proceeds as of the filing date.
• Regulatory Status: The company received "Breakthrough Device" designation from the FDA for its aortic stenosis algorithm in June 2025. It is preparing a 510(k) submission for the MyoVista wav ECG device, though recent updates to echocardiography guidelines require evaluation of algorithm alignment prior to submission.
• Going Concern: The independent auditor issued an opinion with an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and limited capital resources.

Guidance, Risks, and Contingencies

• Liquidity Risk: With approximately $1.1 million in cash as of April 30, 2025, management states that current resources are insufficient to fund operations for the next twelve months. Additional equity or debt financing is required to continue R&D, clinical studies, and potential commercialization.
• Regulatory Risk: Future success is entirely dependent on obtaining FDA clearance for the MyoVista wav ECG and Cloud Platform. Failure to obtain clearance, or delays in the process, would prevent U.S. sales and likely cause business failure.
• Nasdaq Compliance: The company received notice from Nasdaq in March 2025 regarding non-compliance with the minimum stockholders' equity requirement ($2.5 million). The company was granted an extension until September 15, 2025, to regain compliance. Failure to do so could result in delisting.
• Internal Controls: Management identified material weaknesses in internal control over financial reporting, including lack of proper approval processes and insufficient accounting resources. Remediation is ongoing but not yet complete.
• Intellectual Property: The company relies heavily on license agreements with Mount Sinai for key AI algorithms. Termination of these licenses would prevent commercialization of anticipated products.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $3.1 million raised in the Series D offering (post-fiscal year) to cover operating expenses until FDA clearance is achieved.
• Nasdaq Compliance Plan: Monitor the company's progress in meeting the $2.5 million stockholders' equity requirement by the September 15, 2025 deadline to avoid delisting.
• FDA Submission Timeline: Confirm the status of the 510(k) submission for the MyoVista wav ECG, specifically regarding the alignment with new American Society of Echocardiography guidelines released in July 2025.
• Debt Obligations: Review the terms of the Streeterville Note and FRV Note, including interest rates, maturity dates, and potential conversion features that could lead to significant dilution.
• Internal Control Remediation: Assess the timeline and effectiveness of the remediation plan for the identified material weaknesses in internal controls over financial reporting.